NASDAQ:NYMX Nymox Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nymox Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.43 +0.06 (+2.53 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.34Now: $2.43▼$2.4650-Day Range$2.37MA: $2.77▼$3.3052-Week Range$1.66Now: $2.43▼$4.79Volume188,161 shsAverage Volume215,513 shsMarket Capitalization$176.71 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nymox Pharmaceutical. Previous Next 2.5 Community Rank Outperform VotesNymox Pharmaceutical has received 149 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNymox Pharmaceutical has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentNymox Pharmaceutical has received 50.83% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote “Outperform” if you believe NYMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNymox Pharmaceutical does not currently pay a dividend.Dividend GrowthNymox Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nymox Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders54.00% of the stock of Nymox Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.88% of the stock of Nymox Pharmaceutical is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nymox Pharmaceutical is -15.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nymox Pharmaceutical is -15.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNymox Pharmaceutical has a P/B Ratio of 48.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NYMX Previous Symbol CUSIPN/A CIK1018735 Webwww.nymox.com Phone800-936-9669Debt Debt-to-Equity Ratio0.09 Current Ratio0.44 Quick Ratio0.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales1,472.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book48.60Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,160,000.00 Net Margins-14,341.11% Return on Equity-451.84% Return on Assets-246.37%Miscellaneous EmployeesN/A Outstanding Shares72,719,000Market Cap$176.71 million Next Earnings Date11/11/2020 (Estimated) OptionableOptionable $2.43 +0.06 (+2.53 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NYMX News and Ratings via Email Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter. Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions How has Nymox Pharmaceutical's stock been impacted by Coronavirus (COVID-19)? Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NYMX stock has increased by 6.1% and is now trading at $2.43. View which stocks have been most impacted by COVID-19. When is Nymox Pharmaceutical's next earnings date? Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Nymox Pharmaceutical. How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Corp (NASDAQ:NYMX) issued its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. Nymox Pharmaceutical had a negative net margin of 14,341.11% and a negative return on equity of 451.84%. View Nymox Pharmaceutical's earnings history. Are investors shorting Nymox Pharmaceutical? Nymox Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,550,000 shares, an increase of 12.0% from the August 15th total of 3,170,000 shares. Based on an average trading volume of 264,100 shares, the days-to-cover ratio is currently 13.4 days. Currently, 8.1% of the company's stock are short sold. View Nymox Pharmaceutical's Short Interest. Who are some of Nymox Pharmaceutical's key competitors? Some companies that are related to Nymox Pharmaceutical include Celldex Therapeutics (CLDX), Quotient (QTNT), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), Vermillion (VRML), Riot Blockchain (RIOT), Biomerica (BMRA), Trinity Biotech (TRIB), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF), Akers Biosciences (AKER), BG Medicine (BGMD) and Fluoropharma Medical (FPMI). View all competitors. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA). Who are Nymox Pharmaceutical's key executives? Nymox Pharmaceutical's management team includes the following people: Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)Mr. Erik Danielsen, Chief Financial Officer (Age 56)Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55) What is Nymox Pharmaceutical's stock symbol? Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX." Who are Nymox Pharmaceutical's major shareholders? Nymox Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nuveen Asset Management LLC (0.21%), Bank of New York Mellon Corp (0.13%), Strs Ohio (0.12%), California Public Employees Retirement System (0.12%), Charles Schwab Investment Management Inc. (0.12%) and Jane Street Group LLC (0.12%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View institutional ownership trends for Nymox Pharmaceutical. Which institutional investors are selling Nymox Pharmaceutical stock? NYMX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Patriot Financial Group Insurance Agency LLC. View insider buying and selling activity for Nymox Pharmaceutical. Which institutional investors are buying Nymox Pharmaceutical stock? NYMX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Strs Ohio, Charles Schwab Investment Management Inc., California Public Employees Retirement System, Jane Street Group LLC, New York State Common Retirement Fund, and Virtu Financial LLC. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson, and Randall J Lanham. View insider buying and selling activity for Nymox Pharmaceutical. How do I buy shares of Nymox Pharmaceutical? Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nymox Pharmaceutical's stock price today? One share of NYMX stock can currently be purchased for approximately $2.43. How big of a company is Nymox Pharmaceutical? Nymox Pharmaceutical has a market capitalization of $176.71 million and generates $120,000.00 in revenue each year. What is Nymox Pharmaceutical's official website? The official website for Nymox Pharmaceutical is www.nymox.com. How can I contact Nymox Pharmaceutical? Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
